Drug Trial Radar · NCT06344052
To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Sep 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Apr 9, 2024
Primary completion
Sep 30, 2026
Study completion Mar 30, 2029
Sponsor
- Lead sponsor
- Stamford Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy of using SP-002 in participants with locally advanced Basal cell carcinoma. The main question it aims to answer is what the objective response rate for a basal cell carcinoma tumor is following 1 or 3 cycles of SP-002 treatment given as an add-on to hedgehog pathway inhibitor therapy. Researchers will compare the objective response rate for treated Basal cell carcinoma tumors between 3 treatment Arms. * Arm 1 participants will receive daily hedgehog pathway inhibitor, and 3 cycles of SP-002 treatment. * Arm 2 participants will receive daily hedgehog pathway inhibitor, and 1 cycle of SP-002 treatment. * Arm 3 participants will receive daily hedgehog pathway inhibitor only.
Conditions
- Basal Cell Carcinoma
Interventions
SP-002Drug
SP-002 is a replication deficient adenovirus-5 encoding human interferon gamma (IFNγ), designed for intra-tumoral administration
VismodegibDrug
The HHPI vismodegib is currently indicated for the treatment of adult patients with metastatic BCC, or with laBCC where surgery and/or radiation therapy are not appropriate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: Week 26
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona · Recruiting
Research Site
Boca Raton, Florida · Recruiting
Research Site
Coral Springs, Florida · Recruiting
Research Site
Cutler Bay, Florida · Recruiting
Research Site
Rockville, Maryland · Recruiting
Research Site
Lee's Summit, Missouri · Recruiting
Research Site
Rochester, New York · Recruiting
Research Site
Cedar Park, Texas · Recruiting
Research Site
Humble, Texas · Recruiting
Research Site
Longview, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.